Business Wire

U.S. Ambassador Johnson and UK’s Sir Nicholas Soames to join Bermuda Premier at Executive Forum in London

Share

The United States Ambassador to the United Kingdom (UK), Robert Wood Johnson, and the UK’s Rt. Hon. Sir Nicholas Soames, former defence minister and former Conservative Member of Parliament for Mid Sussex, will join Bermuda’s Premier, the Hon. E. David Burt, JP, MP, at an Executive Forum in London this month to highlight the historic and successful economic relationship that exists between Bermuda, the U.S. and the UK.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191113005627/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bermuda Executive Forum London 2019 opening panel. (Photo: Business Wire)

The keynote conversation between Ambassador Johnson, Sir Nicholas Soames and the Premier will explore the implications of global trends, address key challenges from Brexit to U.S. tax reform, and shed light on new opportunities to further develop economic ties. The discussion will be moderated by Fiona Luck, a Non-Executive Director on the Lloyd’s of London Franchise Board, whose more than 30 years’ experience in insurance and reinsurance will bring valuable insights from Bermuda’s traditional powerhouse industry, a significant contributor to the world’s economy.

Under the theme ‘Navigating Disruption for Positive Change’, the Bermuda Executive Forum London takes place Tuesday, November 26 and is hosted by the Bermuda Business Development Agency (BDA). It will bring together government officials, regulators and industry leaders for a full-day agenda of engaging panel discussions and keynotes across a range of sectors including re/insurance, asset management, family offices, financial services and technology. A networking reception will close the event in the evening.

“We look forward to welcoming Ambassador Johnson and Sir Nicholas Soames to our forum in London. Their participation, alongside our Premier, will ensure a dynamic and informative start to the day,” said Roland Andy Burrows, CEO of the BDA. “The U.S. and the UK are highly valued Bermuda partners and we have long enjoyed robust, mutually beneficial relationships that continue to thrive in many areas. As world-leading and innovative financial centres there’s clearly a lot of common ground for collaboration where we can work together to grow business and investment for the benefit of all.”

Ambassador Johnson was nominated by President Trump on June 22, 2017. He made his first official visit to Bermuda in July this year when he spoke about the strength and long-term nature of Bermuda’s relationship with the U.S. and expressed his admiration for the island’s unique capabilities and world-class expertise.

A prominent businessman and philanthropist, Ambassador Johnson served for more than 30 years as the Chairman and CEO of The Johnson Company, a private asset management firm founded in 1978, and as the Chairman and CEO of the New York Jets football team and New York Jets Foundation. He is the Founding Chairman of the Lupus Research Alliance and worked for many years with the Juvenile Diabetes Research Foundation.

Former Conservative Party grandee and grandson of the great wartime leader Sir Winston Churchill, Sir Nicholas served until recently as the Member of Parliament for Mid Sussex. Prior to that, he was the UK Minister of State for the Armed Forces from 1994-1997. Having previously worked as a stockbroker and on the staff of a U.S. Senator in Washington D.C, he has specialist knowledge in the fields of Europe, defence, international affairs, aviation and trade and industry. He also has a longstanding involvement in the Insurance and Reinsurance business as a Senior Advisor to Marsh the Global Leader in Broking and Risk Management. In March earlier this year, Sir Nicholas met with Premier Burt as part of a wider Bermuda Government trip to the UK and Brussels.

Mr Burrows added, “Against a backdrop of global economic and digital disruption, our event provides a platform for an open dialogue on how best to embrace change to bring about positive transformations and future growth. It is an ideal opportunity to directly engage with partners in the UK market, to share knowledge and forge new connections with prospective businesses and investors who would benefit from Bermuda’s global connectivity combined with its quality, stability and ease of doing business.”

The BDA forum builds on a two-day event held in London last year opened by Premier Burt with more than 50 experts as speakers and panellists. The event attracted close to 200 delegates encompassing a wide range of industries, and featured the UK’s Chris Holmes, Lord of Richmond MBE, and Bermudian Chief Executive of American International Group (AIG), Brian Duperreault.

To register for the Bermuda Executive Forum London 2019, click here.

CONNECTING BUSINESS

The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA CONTACT:
Nicola Stevens
Director of Communications and PR
nstevens@bda.bm
+1 441 292 7774

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye